These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26193935)

  • 1. Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.
    Zhou N; Xu W; Zhang Y
    Drug Discov Ther; 2015 Jun; 9(3):147-55. PubMed ID: 26193935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
    Vancurova I; Uddin MM; Zou Y; Vancura A
    Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors in cancer therapy. A review.
    Hrabeta J; Stiborova M; Adam V; Kizek R; Eckschlager T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):161-9. PubMed ID: 24263215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging roles of HDACs and their therapeutic implications in cancer.
    Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
    Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
    Luan Y; Li J; Bernatchez JA; Li R
    J Med Chem; 2019 Apr; 62(7):3171-3183. PubMed ID: 30418766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
    Hess-Stumpp H
    Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.
    Zhang L; Han Y; Jiang Q; Wang C; Chen X; Li X; Xu F; Jiang Y; Wang Q; Xu W
    Med Res Rev; 2015 Jan; 35(1):63-84. PubMed ID: 24782318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
    Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
    Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.
    Sharma S; Taliyan R
    Pharmacol Res; 2015 Oct; 100():157-69. PubMed ID: 26254871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors and chaperone function.
    Rao R; Fiskus W; Ganguly S; Kambhampati S; Bhalla KN
    Adv Cancer Res; 2012; 116():239-62. PubMed ID: 23088873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.